Localised prostate cancer: Current treatment options

Australian Family Physician

Volumn 40, Issue 10, 2011, Pages 768-771

  Duchesne, Gillian ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Prostatectomy; Prostatic neoplasms treatment; Radiotherapy

Indexed keywords

ARTICLE; CANCER GRADING; CANCER STAGING; HUMAN; MALE; PATHOLOGY; PROSTATE TUMOR; PROSTATECTOMY; WATCHFUL WAITING;

HUMANS; MALE; NEOPLASM GRADING; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS; WATCHFUL WAITING;

EID: 84855913153     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Australian Institute of H ealth and Welfare. Cancer. Available at www.aihw.gov.au/cancer/#incidence.
2. Sobin LH, Gospodarowicz M K, Wittekind CH, editors. TNM classification of malignant tumors, 7th edn. Oxford: Wiley-Blackwell, 2009.
3. Smith DP, King M T, Egger S, et al. Quality of life three years after diagnosis of localised prostate cancer; a population based cohort study. BMJ 2009;339:b4817.
4. Gleason DF. The Veteran's Administration Cooperative Urologic Research Group: histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M, editor. Urologic pathology: the prostate. Philadelphia: Lea and Febiger, 1977; p. 171-98.
5. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010;8:162-200.
6. Katz M S, Efstasthiou JA, D'Amico AV, et al. The 'CaP Calculator': an on-line decision support tool for clinically localized prostate cancer. BJU Int 2010;105:1417-22.
7. Klotz L, Zhang L, Lam A, et al. Clinical results of long-term follow-up of a large active surveillance cohort with localised prostate cancer. J Clin Oncol 2010;28:126-31.
8. Duthie JB, Pickford JE, Gilling PJ. Robot-assisted laparoscopic prostatectomy: a 2010 update. N Z Med J 2010;123:30-4.
9. Menon M, Shrivastava A, Tewari A. Laparoscopic radical prostatectomy: conventional and robotic. Urology 2005;66(S5):101-4.
10. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007;177:2106-31.
11. Open clinical trial: Trans Tasman Radiation Oncology Group (TROG) 08.03. A phase III multi-centre randomised trial comparing adjuvant radiotherapy (RT) with surveillance and early salvage RT in patients with positive margin or extraprostatic disease following radical prostatectomy (RAVES: Radiotherapy - Adjuvant Versus Early Salvage).
12. Pickles T, Phillips N. The risk of second malignancy in men with prostate cancer treated with or without radiation in British Columbia, 1984-2000. Radiother Oncol 2002;65:145-51.
13. Crook J. The role of brachytherapy in the definitive management of prostate cancer. Cancer Radiother 2011;15:230-7.
14. Bolla M, de Reijke TM, van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J M ed 2009;360:2516-27.
15. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised trial. Lancet Oncol 2005;6:841-50.
16. Cancer Council Australia. Available at www.cancer.org.au//aboutcancer/cancertypes/prostatecancer.htm.
17. Pound CR, Parton AW, Eisenberger M A, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
18. Open clinical trial: Victorian Cancer Council PR01-03 and Trans Tasman Radiation Oncology Group (TROG) 03.06. A collaborative randomised phase III trial: the timing of intervention with androgen deprivation in prostate cancer patients with a rising PSA (TOAD: Timing of Androgen Deprivation).